melanocortin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
=== Marijuana === Similar to alcohol, marijuana is absorbed into the bloodstream and crosses the blood brain barrier. Notably, the THC released from marijuana binds to the CB-1 cannabinoid receptors, inducing various effects. These effects encompass mood changes, altered perception of time, and heightened sensitivity, among others.
Wadi al-Taym is named after the Arab tribe of Taym Allat (later Taym-Allah) ibn Tha'laba. The Taym-Allat entered the Euphrates Valley and adopted Christianity in the pre-Islamic period before ultimately embracing Islam after the 7th-century Muslim conquests. A small proportion of the tribe took up abode in the Wadi al-Taym at some point during the first centuries of Muslim rule. The Taym Allah, and the largely Christian, core tribes of the Lahazim in general, appear to have fought against the Muslim conquests of eastern Arabia in the Ridda wars (632–633) and the lower Euphrates in modern Iraq afterward. They embraced Monophysite Christianity, like many Bakrites, before the advent of Islam in the 620s–630s. This valley became one of the first places where the heterodox Druze faith, which branched out of Isma'ili Shia Islam, took root in the 11th century. The Wadi al-Taym was the first area where the Druze appeared in the historical record under the name "Druze". According to many of the genealogical traditions of the Druze feudal families, the feudal Druze clans claimed descent from Arab tribes originally based in eastern Arabia and which entered Syria after periods of settlement in the Euphrates Valley. According to the historian Nejla Abu-Izzedin, "ethnically", the "Wadi al-Taym has been authoritatively stated to be one of the most Arab regions of [geographical] Syria". The area was one of the two most important centers of Druze missionary activity in the 11th century. Wadi al-Taym is generally considered the "birthplace of the Druze faith".
== Release history == Reek of Putrefaction was first released in 1988. When released, Reek of Putrefaction reached No. 6 on the UK Indie Chart, establishing Carcass' earlier grindcore sound. The late BBC Radio 1 DJ John Peel declared it his favourite album of 1988, in an interview for British newspaper The Observer. Reek of Putrefaction was re-released in 1994. In 2002, the album was reissued. The album was re-released in 2008 as part of an ongoing series of Carcass reissues to tie in with their reunion. The main album, along with the demo Flesh Ripping Sonic Torment, is presented as one side of a dualdisc, while the DVD side features the first part of an extended documentary titled The Pathologist's Report Part I: Incubation. Later editions contain the album on a CD and the documentary on a separate DVD. The album is presented in a 12-panel digipak with full lyrics and artwork and is sealed in a white medical bag with sticker, to hide the controversial cover art.
A refrigerated cargo ship, also known as a reefer ship, is a refrigerated cargo ship typically used to transport perishable cargo, which require temperature-controlled handling, such as fruits, meat, vegetables, dairy products, and similar items.
DMSO is a polar aprotic solvent and is less toxic than other members of this class, such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, and hexamethylphosphoramide (HMPA). DMSO is frequently used as a solvent for chemical reactions involving salts, most notably Finkelstein reactions and other nucleophilic substitutions. It is also extensively used as an extractant in biochemistry and cell biology. Because DMSO is only weakly acidic, it tolerates relatively strong bases and as such has been extensively used in the study of carbanions. A set of non-aqueous pKa values (C-H, O-H, S-H and N-H acidities) for thousands of organic compounds have been determined in DMSO solution. Because of its high boiling point, 189 °C (372 °F), DMSO evaporates slowly at normal atmospheric pressure. Samples dissolved in DMSO cannot as easily be recovered compared to other solvents, as it is very difficult to remove all traces of DMSO by conventional rotary evaporation. One technique to fully recover samples is removal of the organic solvent by evaporation followed by addition of water (to dissolve DMSO) and cryodesiccation to remove both DMSO and water. Reactions conducted in DMSO are often diluted with water to precipitate or phase-separate products. The relatively high freezing point of DMSO, 18.5 °C (65.3 °F), means that at, or just below, room temperature it is a solid.
Sources: en.wikipedia.org
=== Self-treatment === If an individual recognizes the symptoms of hypoglycemia coming on, blood sugar should promptly be measured, and a sugary food or drink should be consumed. The person must be conscious and able to swallow. The goal is to consume 10–20 grams of a carbohydrate to raise blood glucose levels to a minimum of 70 mg/dL (3.9 mmol/L). Examples of products to consume are:
== Analysis == According to author Daniel Leonard Bernardi in his book, Star Trek and History: Race-ing Toward a White Future: "Like the Federation, the Comms [sic] have full command of the English language (although they speak with a homogenized 'Asian' accent). The beginning of the episode thus shows that those with white skin can be uncivilized savages and those with yellow skin can be civilized and rational [...] This would be counter to the hegemonic representation of Asians in the United States media; that diverse collective of peoples are consistently constructed in film and television as a menacing 'yellow horde.'" Bernardi goes on to say:
Asilomar conference on recombinant DNA Genetic engineering Genetically modified organism Recombinant virus Vector DNA Biomolecular engineering Recombinant DNA technology Host cell protein T7 expression system
Einstein hosts one of the three inaugural MSTPs launched by the National Institutes of Health (NIH) in 1964. This fully-funded dual doctoral MD/PhD program provide integrated graduate and clinical training for aspiring physician-scientists. The MSTP includes waived tuition, a stipend, subsidized housing, and a sesquiennial retreat to the Edith Macy Conference Center. The first year of the program integrates medical school preclerkship curriculum with graduate school coursework and lab rotations. In the second year, trainees complete preclinical medical courses, take USMLE Step 1, and choose a PhD advisor based on lab rotations. Years three to five focus on PhD research, publication, and optional clinical activities, followed by intensive clinical clerkships in years six and seven after dissertation defense. While working in the lab, students engage in both pathology case studies and clinics to maintain clinical skills.
Sources: en.wikipedia.org
This 43S preinitiation complex (43S PIC) accompanied by the protein factors moves along the mRNA chain toward its 3'-end, in a process known as 'scanning', to reach the start codon (typically AUG). In eukaryotes and archaea, the amino acid encoded by the start codon is methionine. The Met-charged initiator tRNA (Met-tRNAiMet) is brought to the P-site of the small ribosomal subunit by eukaryotic initiation factor 2 (eIF2). It hydrolyzes GTP, and signals for the dissociation of several factors from the small ribosomal subunit, eventually leading to the association of the large subunit (or the 60S subunit). The complete ribosome (80S) then commences translation elongation. Regulation of protein synthesis is partly influenced by phosphorylation of eIF2 (via the α subunit), which is a part of the eIF2-GTP-Met-tRNAiMet ternary complex (eIF2-TC). When large numbers of eIF2 are phosphorylated, protein synthesis is inhibited. This occurs under amino acid starvation or after viral infection. However, a small fraction of this initiation factor is naturally phosphorylated. Another regulator is 4EBP, which binds to the initiation factor eIF4E and inhibits its interactions with eIF4G, thus preventing cap-dependent initiation. To oppose the effects of 4EBP, growth factors phosphorylate 4EBP, reducing its affinity for eIF4E and permitting protein synthesis.
The first fully terrestrial vertebrates were amniotes. Like their amphibious early tetrapod predecessors, they had lungs and limbs. Amniotic eggs, however, have internal membranes that allow the developing embryo to breathe but keep water in. Hence, amniotes can lay eggs on dry land, while amphibians generally need to lay their eggs in water. The first amniotes apparently arose in the Pennsylvanian subperiod of the Carboniferous. They descended from earlier reptiliomorph amphibious tetrapods, which lived on land that was already inhabited by insects and other invertebrates as well as ferns, mosses and other plants. Within a few million years, two important amniote lineages became distinct: the synapsids, which would later include the common ancestor of the mammals; and the sauropsids, which now include turtles, lizards, snakes, crocodilians and dinosaurs (including birds). Synapsids have a single hole (temporal fenestra) low on each side of the skull. Primitive synapsids included the largest and fiercest animals of the early Permian such as Dimetrodon. Nonmammalian synapsids were traditionally—and incorrectly—called "mammal-like reptiles" or pelycosaurs; we now know they were neither reptiles nor part of reptile lineage. Therapsids, a group of synapsids, evolved in the Middle Permian, about 265 million years ago, and became the dominant land vertebrates. They differ from basal eupelycosaurs in several features of the skull and jaws, including: larger skulls and incisors which are equal in size in therapsids, but not for eupelycosaurs.
Barker countersued for slander, but Hallstrom prevailed, receiving a settlement in 2005. Though she was not required to sign a non-disclosure agreement, she limited her comments about Barker until after his death, fearing retribution from him. In October 2007, Deborah Curling, a CBS employee assigned to The Price Is Right, filed a lawsuit against CBS, Bob Barker, and The Price Is Right producers, claiming that she was forced to quit her job after testifying against Barker in a wrongful-termination lawsuit brought by a previous show producer. Curling claimed that she was demoted to an "intolerable work environment" backstage, which caused her to leave the job. Curling, who is black, also alleged that the show's producers, including Barker, created a hostile work environment in which black employees and contestants were discriminated against. A few months later, Barker was removed from the lawsuit, and in September 2009, the lawsuit was dismissed. Curling's attorney stated that he planned to appeal the dismissal of the lawsuit. In January 2012, the California Court of Appeals affirmed the dismissal.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.